ONCOLOGY

ONCOLOGY | PARTNERSHIPS

Odimma Therapeutics present at BIO-Europe Spring 2023
March 28, 2023June 9, 2026

——————— Odimma Therapeutics participated in BIO-Europe Spring 2023, held in Basel, Switzerland, one of Europe’s leading partnering events for the biotechnology and life sciences industry. The conference brought together biotechnology companies, pharmaceutical leaders, investors and healthcare innovators from around the world to explore strategic collaborations and emerging opportunities across the sector. Participation in BIO-Europe Spring supported…

Read More Odimma Therapeutics present at BIO-Europe Spring 2023
ONCOLOGY | PARTNERSHIPS | PLATFORM

Strategic Clinical Collaboration Established with myNEO
February 13, 2023June 9, 2026

——————— Odimma Therapeutics and myNEO announced a strategic clinical collaboration focused on advancing the development of ODI-2001, Odimma’s personalized DNA-based cancer immunotherapy platform. The collaboration combines Odimma Therapeutics’ synthetic DNA immunotherapy technology with myNEO’s artificial intelligence-driven neoantigen discovery platform to support the identification and selection of patient-specific neoantigen targets designed to generate strong anti-tumor immune…

Read More Strategic Clinical Collaboration Established with myNEO
ONCOLOGY | PARTNERSHIPS

Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight
December 7, 2022June 9, 2026

——————— Enabling the Next Generation of Personalized Cancer Immunotherapy with Synthetic DNA Manufacturing. Odimma Therapeutics has established a strategic partnership with Touchlight, the UK biotechnology company pioneering enzymatic DNA production, to support the clinical development of its personalized cancer immunotherapy platform. The collaboration provides Odimma with access to Touchlight’s proprietary doggybone DNA (dbDNA™) technology, a next-generation synthetic…

Read More Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight
CORPORATE | EVENTS | ONCOLOGY

Odimma Therapeutics Showcases Its Personalized Immunotherapy Platform at the 5th Neoantigen Summit Europe
April 27, 2022June 10, 2026

——————— Advancing the Future of Precision Oncology. Odimma Therapeutics presented its personalized cancer immunotherapy platform at the 5th Neoantigen Summit Europe, held in Amsterdam in April 2022. The company shared its innovative approach to neoantigen-based immunotherapy with leading scientists, biotechnology companies and industry experts specializing in precision oncology. The summit provided an important opportunity to highlight Odimma’s vision…

Read More Odimma Therapeutics Showcases Its Personalized Immunotherapy Platform at the 5th Neoantigen Summit Europe
CORPORATE | ONCOLOGY | PARTNERSHIPS

ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy
April 17, 2022June 9, 2026

——————— Strengthening Manufacturing Capabilities for the ODI-2001 Platform. Odimma Therapeutics and ABL Europe, a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, entered into a strategic development agreement to support the advancement of ODI-2001, Odimma’s personalized cancer immunotherapy platform. Under the collaboration, ABL will manufacture the viral component of ODI-2001, a key element…

Read More ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy
CORPORATE | ONCOLOGY | PLATFORM

Odimma Therapeutics Secures €2 Million to Advance Its Personalized Cancer Immunotherapy Platform
December 18, 2019June 10, 2026

——————— Seed Financing Supports the Transition Toward Clinical Development. In 2019, Odimma Therapeutics secured €2 million in seed funding, combining a €1 million investment led by Cap Innov’Est with €1 million in support from Bpifrance’s Deeptech program. The financing marked a major milestone in the company’s development, providing the resources needed to advance its proprietary personalized cancer immunotherapy platform…

Read More Odimma Therapeutics Secures €2 Million to Advance Its Personalized Cancer Immunotherapy Platform